Lactose (India) Limited Secures BSE Approval for Vitanosh Ingredients Merger

Lactose (India) Limited , a prominent player in the pharmaceutical industry, has reached a significant milestone in its proposed merger with Vitanosh Ingredients Private Limited. The company recently received a no-objection observation letter from BSE Limited, marking a crucial step forward in the amalgamation process.

Key Highlights of the Merger Approval

• BSE Approval Date: The BSE issued the no-objection letter on August 22, 2025.
• Nature of Approval: The letter contained 'no adverse observations' regarding the proposed merger.
• Legal Framework: The scheme of amalgamation falls under Sections 230 to 232 of the Companies Act, 2013.
• Board Approval: The merger scheme was initially approved by the Board of Directors in October 2024.

Implications and Next Steps

The receipt of the no-objection letter from BSE is a positive development for Lactose (India) Limited. However, it's important to note that this approval is just one step in the broader merger process. The company still needs to secure other regulatory and statutory approvals before the merger can be finalized.

Transparency Measures

In line with corporate governance practices, Lactose (India) Limited has made the BSE observation letter available on its official website. This move allows shareholders and other interested parties to access and review the document, ensuring transparency in the merger proceedings.

Looking Ahead

While this approval from BSE is a significant milestone, the merger between Lactose (India) Limited and Vitanosh Ingredients Private Limited remains subject to additional regulatory scrutiny. Stakeholders and market observers will be keenly watching the next steps in this corporate restructuring process.

As the merger progresses, it could potentially impact the company's market position and operational dynamics. However, the full implications of this amalgamation will only become clear as the process unfolds and receives all necessary approvals.